Home » Clinical Trials » Medical Areas
Therapeutic Areas: Gastroenterology
Disease Category: Crohn's Disease

Trial Information

Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

C87065 (COSPAR II): An Open-Label, Multi-Center Trial to Examine the Long Term Safety, Efficacy, and Corticosteroid-Sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease Previously Enrolled in the Trial C87059 (COSPAR I).

This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease previously enrolled in COSPAR I.

Inclusion Criteria:

• Patients previously enrolled in C87059.

Exclusion Criteria:

• Subject withdrawn or discontinued from -059 study under specific conditions.
• Subject who received treatment other than study medication and other than medications permitted in the -059 study.
• Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment.

UCB Clinical Trial Call Center
Located in:
Rochester MN
Phone: 1-877-822-9493

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.